{"product_id":"cagrilintide","title":"Cagrilintide","description":"\u003cp\u003eCagrilintide takes obesity treatment in a different direction by targeting amylin, a hormone co-secreted with insulin from pancreatic beta cells. Amylin naturally promotes satiety, slows gastric emptying, and suppresses glucagon—effects that complement GLP-1 but through distinct pathways. The problem with native amylin is it's short-lived and tends to aggregate. Cagrilintide is an acylated analog designed for once-weekly dosing with improved stability. Alone, it produces meaningful weight loss, but the real excitement is the combination with semaglutide (called CagriSema). Phase 2 trials showed this combination produces weight loss approaching 25%—potentially the most effective obesity treatment ever tested. By hitting both amylin and GLP-1 pathways, you get additive appetite suppression through different brain circuits. Novo Nordisk is racing this through development as the potential successor to Wegovy. Cagrilintide represents the emerging understanding that obesity is a multi-pathway disease requiring multi-pathway treatment.\u003c\/p\u003e","brand":"Peptoris Labs","offers":[{"title":"10mg","offer_id":57534600249675,"sku":null,"price":85.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1047\/3599\/8283\/files\/5_2.png?v=1781008202","url":"https:\/\/peptorislabs.com\/products\/cagrilintide","provider":"Peptoris Labs","version":"1.0","type":"link"}